Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors
Clinical Evaluation of 323U66 SR in Patients With Depression - Placebo-controlled, Double-blind, Comparative Study in Patients With Depression Who Did Not Respond Sufficiently to Selective Serotonin Re-uptake Inhibitors
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Depressive Disorder and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Oct 2018 — Jan 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jul 2017 [monthly]
Completed PHASE3
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aichi, Japan , Chiba, Japan , Fukuoka, Japan , Fukushima, Japan , Hokkaido, Japan , Hyōgo, Japan , Ibaraki, Japan , Ishikawa, Japan , Kagawa, Japan , Kanagawa, Japan and 7 more locations